SOPHiA GENETICS (NASDAQ:SOPH) Releases Quarterly Earnings Results, Misses Estimates By $0.04 EPS

Key Points

• Q1 results: SOPHiA reported EPS of ($0.27), missing estimates by $0.04, while revenue grew 22% YoY to $21.7M with a record 108,000 genomic analyses, a 75.4% adjusted gross margin and net dollar retention of 117%.
• Guidance and profitability path: The company reaffirmed 2026 revenue guidance of $92–$94M and expects an adjusted EBITDA loss of $29–$32M, targeting adjusted-EBITDA breakeven by end-2026 and positive EBITDA in H2 2027.
• Risks and cash burn: Near-term headwinds include Guardant patent litigation (Q1 legal expense ~$1.4M), Swiss franc FX pressure, regional softness and elevated Q1 cash burn of $19.5M despite $65.4M cash on hand, while analyst views remain mixed (consensus "Hold", $7.50 target).

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) posted its earnings results on Tuesday. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.04), Zacks reports. SOPHiA GENETICS had a negative return on equity of 50.60% and a negative net margin of 44.22%.

Here are the key takeaways from SOPHiA GENETICS's conference call:

• Q1 results — revenue of $21.7M (+22% YoY), a record 108,000 genomic analyses, and a 75.4% adjusted gross margin, which management says demonstrates the platform's scalability.
• Network and retention — 537 institutional customers across 75 countries and ~2.5M profiles since inception; net dollar retention rose to 117% with multiple >$1M ACV expansion deals, supporting in-account upsell momentum.
• Biopharma traction — accelerating engagement with partners including AstraZeneca and J&J, plus efforts to build a global CDx and real-world evidence offering that management expects will be a material growth driver.
• Outlook and profitability path — the company reaffirmed 2026 revenue guidance of $92–$94M (20–22% growth) and adjusted EBITDA loss guidance of $29–$32M, and expects to approach adjusted-EBITDA breakeven by end-2026 and turn positive in H2 2027.
• Risks and headwinds — ongoing Guardant patent litigation (Q1 legal expense ~$1.4M, net ~$700k after interim recoveries), Swiss franc FX translation pressure raising dollar-reported costs, softness in Latin America, and elevated Q1 cash burn of $19.5M despite $65.4M cash on hand.

SOPHiA GENETICS Price Performance

NASDAQ:SOPH traded down $0.14 during mid-day trading on Tuesday, hitting $5.15. 46,688 shares of the stock traded hands, compared to its average volume of 166,283. SOPHiA GENETICS has a 12-month low of $2.59 and a 12-month high of $5.70. The company has a market cap of $352.72 million, a PE ratio of -10.10 and a beta of 1.01. The company has a quick ratio of 1.84, a current ratio of 1.96 and a debt-to-equity ratio of 1.01. The business's 50-day moving average price is $4.81 and its 200 day moving average price is $4.78.

Wall Street Analyst Weigh In

Several brokerages recently commented on SOPH. BTIG Research boosted their price objective on shares of SOPHiA GENETICS from $7.00 to $8.00 and gave the company a "buy" rating in a research note on Wednesday, April 15th. Guggenheim boosted their price objective on shares of SOPHiA GENETICS from $6.00 to $7.00 and gave the company a "buy" rating in a research note on Monday, January 26th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of SOPHiA GENETICS in a research note on Tuesday, April 21st. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, SOPHiA GENETICS presently has an average rating of "Hold" and a consensus target price of $7.50.

Insider Transactions at SOPHiA GENETICS

In other news, CEO Jurgi Camblong sold 17,473 shares of the company's stock in a transaction on Wednesday, April 15th. The shares were sold at an average price of $5.00, for a total value of $87,365.00. Following the completion of the sale, the chief executive officer owned 3,646,967 shares of the company's stock, valued at approximately $18,234,835. This represents a 0.48% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 193,859 shares of company stock worth $943,777 in the last three months. Insiders own 4.88% of the company's stock.

Institutional Investors Weigh In On SOPHiA GENETICS

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP raised its holdings in SOPHiA GENETICS by 24.7% during the 3rd quarter. Dimensional Fund Advisors LP now owns 31,332 shares of the company's stock valued at $148,000 after buying an additional 6,205 shares during the last quarter. Squarepoint Ops LLC bought a new stake in SOPHiA GENETICS during the 3rd quarter valued at $49,000. Quadrature Capital Ltd bought a new stake in SOPHiA GENETICS during the 4th quarter valued at $54,000. XTX Topco Ltd bought a new stake in SOPHiA GENETICS during the 4th quarter valued at $55,000. Finally, Archon Capital Management LLC raised its holdings in SOPHiA GENETICS by 3.4% during the 4th quarter. Archon Capital Management LLC now owns 441,413 shares of the company's stock valued at $2,061,000 after buying an additional 14,342 shares during the last quarter. 31.59% of the stock is currently owned by institutional investors.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.